Isabella Ciccone, MPH

Amaal Starling, MD, FAHS, FAAN, associate professor of neurology at Mayo Clinic College of Medicine, shared data recently presented at AHS 2025 showing that eptinezumab extended the time between migraine attacks.

New findings from a randomized trial reported no difference in relapse rates or new T2 lesions between a personalized lifestyle app and a nonpersonalized version for multiple sclerosis.

At AAIC 2025, the associate professor in the Department of Psychiatry at McGill University talked about the strengths and limitations of PET and blood biomarkers for Alzheimer disease. [WATCH TIME: 5 minutes]

The director of the Neuroethics Program at Cleveland Clinic discussed the evolving role of ethics in neurological clinical trials, highlighting skill development, safeguards, and patient-centered decision-making.

The physician assistant specializing in Parkinson disease talked about the shared decision-making process when discussing advanced therapies for movement disorder care with patients. [WATCH TIME: 3 minutes]

The nurse practitioner in the Center for Movement Disorders & Neurorestoration at the University of Florida discussed clinical experiences with deep brain stimulation for atypical MS tremor and PD. [WATCH TIME: 5 minutes]

The director of the Movement Disorders Clinic at Houston Methodist Hospital outlined a stepwise approach for identifying, managing, and treating hallucinations in patients with Parkinson disease. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The director of the Adult Genetic Epilepsy Program at the University of Toronto talked about how to ensure a smooth transition from pediatric to adult epilepsy care for university students. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 29, 2025.

The director of the Norman Fixel Institute for Neurological Diseases at UF Health talked about prevention, understanding disease mechanisms, and creating a patient-centered care model in Parkinson disease. [WATCH TIME: 5 minutes]

A recent Canadian study reported similar trends in polysomnography and positive airway pressure initiation over a decade between patients with Parkinson disease and matched controls.

In a recent study, investigators developed multireceptor antagonist peptides that could block CGRP and PACAP, providing proof-of-concept for a potential new approach to targeting pathways involved in migraine.

Spanning the United Kingdom, the United States, European Union, and Japan, the global phase 3 EMPEROR study of zorevunersen is expected to have a data readout by the end of 2027.

The director of the Norman Fixel Institute for Neurological Diseases at UF Health highlighted the need for equitable, worldwide access to levodopa for patients with Parkinson disease. [WATCH TIME: 6 minutes]

Experts shared their clinical perspectives on trending topics in the treatment and management of movement disorders at the 4th Annual Advanced Therapeutics in Movement and Related Disorders (ATMRD) Congress.

Here's some of what is coming soon to NeurologyLive® this week.

At the 2025 ATMRD Congress, a patient advocate living with Parkinson disease emphasized the importance of amplifying patient voices at educational conferences for movement disorders. [WATCH TIME: 5 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 22, 2025.

The professor and chair of neuroscience at UT Southwestern Medical Center discussed how circadian clock genes regulate cellular metabolism and potentially influence headache. [WATCH TIME: 6 minutes]

The headache neurologist at the Barrow Neurological Institute talked about an international expert panel that established agreed-upon definitions for refractory and resistant migraine. [WATCH TIME: 4 minutes]

The decision stemmed from the DREAM study, which found that the Genio system was effective regardless of a patient’s sleeping position, which was particularly important considering patients spend on average 35% to 40% of in a supine position.

At AHS 2025, the associate clinic director at the UC San Diego talked about the cautious use of cannabinoids in migraine and the importance of standard therapies before cannabinoids. [WATCH TIME: 3 minutes]

The director of the Brotman Facial Pain Clinic at the University of Maryland talked about emerging preclinical evidence supporting adenosine A3 receptor activation for post-traumatic trigeminal neuropathic pain. [WATCH TIME: 5 minutes]

At AHS 2025, Elizabeth Seng, PhD, professor of neurology at Albert Einstein College of Medicine, presented findings from a study showing that migraine was associated with increased odds of ischemic stroke in veterans.

The chief scientific officer at Alzheon talked about a symposium on the role of amyloid-beta oligomers in AD and phase 3 clinical data of valiltramiprosate presented at AAIC 2025. [WATCH TIME: 5 minutes]

The physician assistant specializing in Parkinson disease talked about how comorbidities and patient preference guide clinical decisions in prescribing on-demand therapies for Parkinson disease. [WATCH TIME: 5 minutes]

The CEO and cofounder of LSVT Global highlighted the importance of clinicians referring their patients with Parkinson disease early to evidence-based physical therapies, occupational therapies, and speech therapies. [WATCH TIME: 5 minutes]

Scholar Rock’s phase 3 SAPPHIRE trial of apitegromab revealed that the treatment led to improved motor function in patients with spinal muscular atrophy over a 52-week period.

At AAIC 2025, the founder and CEO at Veravas discussed the company’s VeraBIND tau pathology blood test, highlighting its potential to detect Alzheimer disease earlier with high accuracy. [WATCH TIME: 4 minutes]